Insulet Corporation (PODD)

FairStock Score: 41/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for a business whose customers keep coming back and whose economics improve with scale. Insulet fits part of that: it sells the Omnipod insulin-delivery platform, and the filed numbers show real demand. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $801.7M versus $649.1M in fiscal Q2 2025, and net income was $95.0M, an 11.85% margin. Full-year revenue rose from $1.7B in FY2023 to $2.1B in FY2024 and $2.7B in FY2025. That is a fast-growing medical-device franchise, and FairStock's Lynch label calls it a FAST GROWER, citing five-year revenue growth of 24.5% and profit growth of 105.2%. But I am cautious about the price. At the close on 2026-10-13, the shares were $138.13, while FairStock calculates P/E 25.92, P/B 6.73, PEG 29.12, EV/EBITDA 15.31, and a Graham Number of $49.59, a margin of safety of negative 178.54%. The FairStock Score is 41/100. FairStock's return and health calculations are mixed: Altman Z 4.31 looks safe and ROE is 26.02%, but ROCE is 9.71%, D/E is 0.67, Piotroski is 4/9, and FY2025 net income fell to $247.1M from $418.3M in FY2024. FairStock's FCF yield is 2.8% on trailing free cash flow of $265.6M. In sum, this is a good growth business with a durable product ecosystem, but the stock still embeds a lot of optimism. I would want profit growth to confirm the revenue trend before calling the price attractive.

In plain English: Insulet makes insulin delivery systems, mainly the Omnipod pod, for people with diabetes. The business is growing quickly and was profitable in its latest reported quarter, but profits have been uneven over the past few years. The shares look expensive compared with current profits, asset value, and recent growth.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer